[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Upstate Institutional Review Board (IRB) Number:

1417311

Study/Protocol ID:

E19161

Patient Age Group:

Adults

Principal Investigator:

David B Duggan, MD

Where will the study take place?

Upstate Cancer Center
Upstate Cancer Center Hematology Oncology at Oswego
Upstate Cancer Center Hematology Oncology at Oneida

Who can I contact for more information?

Name: Corey Chase
Phone: 315-464-4187
Email: chasec@upstate.edu

Return to Previous Page || Search Again

Top